Clinical autonomic dysfunction in narcolepsy type 1
| Autor: | Elisa Evangelista, Yves Dauvilliers, Sofiene Chenini, Régis Lopez, Lucie Barateau, Isabelle Jaussent |
|---|---|
| Přispěvatelé: | Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Cataplexy Urinary system autonomic dysfunction 03 medical and health sciences SCOPA-AUT Young Adult 0302 clinical medicine Quality of life Physiology (medical) Internal medicine Surveys and Questionnaires medicine Humans Narcolepsy business.industry cataplexy Depression [SCCO.NEUR]Cognitive science/Neuroscience Middle Aged medicine.disease 3. Good health Orexin orexin/hypocretin Autonomic nervous system Sexual dysfunction 030228 respiratory system Autonomic Nervous System Diseases Quality of Life Female Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery Dyslipidemia |
| Zdroj: | SLEEP SLEEP, American Academy of Sleep Medicine, 2019, 42 (12), ⟨10.1093/sleep/zsz187⟩ |
| ISSN: | 1550-9109 0161-8105 |
| Popis: | Study Objectives(1) To compare the presence of autonomic symptoms using the validated SCOPA-AUT questionnaire in untreated patients with narcolepsy type 1 (NT1) to healthy controls, (2) to study the determinants of a high total SCOPA-AUT score in NT1, and (3) to evaluate the effect of drug intake on SCOPA-AUT results in NT1.MethodsThe SCOPA-AUT questionnaire that evaluates gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillomotor, and sexual dysfunction was completed by 92 consecutive drug-free adult NT1 patients (59 men, 39.1 ± 15.6 years old) and 109 healthy controls (63 men, 42.6 ± 18.2 years old). A subgroup of 59 NT1 patients completed the questionnaire a second time, under medication (delay between two evaluations: 1.28 ± 1.14 years).ResultsCompared to controls, NT1 patients were more frequently obese, had more dyslipidemia, with no difference for age and gender. The SCOPA-AUT score of NT1 was higher than in controls in crude and adjusted models. Patients experienced more problems than controls in all subdomains. A higher score in NT1 was associated with older age, longer disease duration, altered quality of life and more depressive symptoms, but not with orexin levels and disease severity. Among patients evaluated twice, the SCOPA-AUT score total did not differ according to treatment status, neither did each subdomain.ConclusionWe captured a frequent and large spectrum of clinical autonomic dysfunction in NT1, with impairment in all SCOPA-AUT domains, without key impact of medication intake. This assessment may allow physicians to screen and treat various symptoms, often not spontaneously reported but associated with poor quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|